Cochrane
Systematic review
May 2025
Patients and professionals
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics
Biologics and newer medicines
Jargon explained
IL-12/23
induction
certainty of evidence
Cochrane
Systematic review
Apr 2025
Patients and professionals
A plain-language summary of a Cochrane review. It concludes that psychological treatments probably give a small improvement in quality of life, depression and anxiety in adults with IBD, and probably improve quality of life in teenagers. Any effect on inflammation or physical symptoms is very uncertain.
Topics
Mental health
Research
Jargon explained
psychological interventions
systematic review
Cochrane (via PMC)
Systematic review
Nov 2019
Patients and professionals
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
Topics
Biologics and newer medicines
Research
Jargon explained
induction
placebo
anti-TNF
Cochrane
Systematic review
Apr 2020
Patients and professionals
A Cochrane review of 14 studies, covering both drug and non-drug treatments such as exercise and psychological approaches, for fatigue in IBD. The reviewers concluded the evidence is too uncertain to say which treatments work and called for trials designed specifically around fatigue.
Topics
Fatigue
Research
Jargon explained
fatigue
systematic review
Cochrane (via PMC)
Systematic review
Aug 2014
Patients and professionals
A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.
Topics
Immunosuppressants
Research
Jargon explained
methotrexate
intramuscular
maintenance
Cochrane
Systematic review
Jul 2023
Patients and professionals
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics
Biologics and newer medicines
Research
Jargon explained
high-certainty evidence
induction
maintenance
integrin
Cochrane
Systematic review
Apr 2020
Patients and professionals
Fatigue is one of the most common complaints in IBD, but this review found too little good-quality research to say which treatments help. The authors call for bigger studies that measure fatigue as the main outcome.
Topics
Fatigue
Research
Jargon explained
fatigue
low certainty evidence
systematic review
cognitive behavioural therapy
Cochrane
Systematic review
Oct 2015
Patients and professionals
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics
Immunosuppressants
Research
Jargon explained
thiopurine
low-quality evidence
adverse event
remission
placebo
systematic review
Cochrane (via PMC)
Systematic review
Aug 2014
Patients and professionals
A Cochrane review concluding that budesonide does not keep Crohn's in remission, especially beyond three months. Small benefits were outweighed by more side effects and adrenal suppression.
Topics
Steroids
Research
Jargon explained
budesonide
maintenance
adrenal suppression
Cochrane (via PMC)
Systematic review
Apr 2008
Patients and professionals
A Cochrane review confirming standard steroids are effective for bringing active Crohn's into remission. They cause more side effects than placebo, and more research was needed on the best length of treatment and how to reduce them.
Topics
Steroids
Research
Jargon explained
corticosteroids
induction
tapering
Cochrane (via PMC)
Systematic review
Nov 2023
Patients and professionals
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics
Biologics and newer medicines
Research
Jargon explained
combination therapy
purine analogue
biosimilar
CT-P13
Cochrane
Systematic review
Feb 2019
Patients and professionals
A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.
Topics
Diet and nutrition
Research
Jargon explained
remission
exclusion diet
randomised controlled trial